SCHEMBL8081029

SCHEMBL8081029

CCOC(=O)CNC(C(=O)N1CCC1C(=O)NOCc1ccc(/C(N)=N/O)cc1)C1CCCCC1

nearest known ligand 0.81

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ F2 P00734 9/20 0.81
▸ ITGB3 P05106 5/20 0.41
▸ ITGA2B P08514 5/20 0.41
▸ PLAT P00750 1/20 0.39
▸ PRSS1 P07477 1/20 0.39
▸ F10 P00742 3/20 0.38
▸ HRH3 Q9Y5N1 1/20 0.32
▸ CTSS P25774 1/20 0.32
▸ FKBP5 Q13451 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8088279 0.92 F2 (0.79) F2ITGB3ITGA2BPLATPRSS1
SCHEMBL8075938 0.91 F2 (0.68) F2ITGB3ITGA2BPLATPRSS1
SCHEMBL8080981 0.91 F2 (0.67) F2ITGB3ITGA2BPLATPRSS1
Ximelagatran SCHEMBL15908919 0.90 F2 (1.00) F2ITGB3ITGA2BPLATPRSS1
Ximelagatran SCHEMBL14509860 0.90 F2 (1.00) F2ITGB3ITGA2BPLATPRSS1
Ximelagatran SCHEMBL19065093 0.90 F2 (1.00) F2ITGB3ITGA2BPLATPRSS1
Ximelagatran SCHEMBL4845 0.90 F2 (1.00) F2ITGB3ITGA2BPLATPRSS1
Ximelagatran SCHEMBL7222774 0.84 F2 (0.88) F2ITGB3ITGA2BPLATPRSS1
SCHEMBL17473611 0.83 F2 (0.73) F2ITGB3ITGA2BPLATPRSS1
SCHEMBL15908918 0.83 F2 (0.73) F2ITGB3ITGA2BPLATPRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009018807-A9 OXAZOLIDINONES AS FACTOR XA INHIBITORS, METHODS FOR THE PRODUCTION THEREOF, AND USE THEREOF IN THERAPY SCHEBO BIOTECH AG (DE) 2009-11-12 — — WO disclosed
WO-2009018807-A1 NOVEL PHARMACEUTICALS, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF IN THERAPY SCHEBO BIOTECH AG (DE) 2009-02-12 — — WO disclosed
Send feedback